Saturday, February 23, 2008

9:00   Opening
G. Comi, SSIF Scientific Committee Member, Italy

9:10   Welcome and Introduction
D. Bates, UK & F. Zipp, Germany

Session 1 – Evolving MS populations

Session Chairs: O. Fernandez, Spain and D. Bates, UK

 

9:30 The changing epidemiology of MS
P.S. Sorensen, Denmark

10:00 The genetics of MS susceptibility and disease course (Quiz)
B. Cree, USA

10:30  Coffee break

11:00 Is the individual disease course in clinical trials predictable? Strengths and pitfalls of data derived from clinical trials
L. Kappos, Switzerland

11:30  Mild/benign MS: myth or reality?
H. Tremlett, Canada

12:00  Discussion

12:30  Lunch

Session 2 – Towards tailored MS therapy

Session Chair: R. Karabudak, Turkey and D. Bates, UK

 

14:00   Disease severity subgroups and treatment
X. Montalban, Spain

14:30   Juvenile MS (Case study)
C.Confavreux, France

15:00 Progressive Forms of MS
J. Sastre-Garriga, Spain

15:30 Benefit to risk: the Cornerstone in MS treatments
D. Goodin, USA

16:00  Coffee break

16:30  Patients’ willingness to take risks (Case study)
P. Rieckmann, Canada

17:00 Factors influencing treatment
M. Sandberg, Sweden

17:30  The real life benefit of DMDs
M. Trojano, Italy

18:00  Discussion

Sunday, February 24, 2008

Session 3 – Emerging treatment strategies in MS

Session Chair: H.P. Hartung, Germany and D. Bates, UK

 

9:00 New oral therapies for the treatment of MS
R. Weissert, Switzerland

9:30 New injectable therapies for the treatment of MS
F. Zipp, Germany

10:00 Coffee break

10:30  Improving current MS therapies (Case study)
G. Comi, Italy

11:00 Emerging neuroprotective strategies in MS
G. Martino, Italy

11:30  Concluding remarks
D. Bates, UK